The BioGRID | PUBLICATION VIEW

	Thromb. Haemost. Jul (2001); 86(1):34-40
AlphaIIbbeta3 and its antagonism at the new millennium.
Plow EF, Cierniewski CS, Xiao Z, Haas TA, Byzova TV
Department of Molecular Cardiology, Cleveland Clinic Foundation, OH 44195, USA. plowe@ccf.org
Abstract: Because of its major role in regulating platelet functions and its prominence on the cell surface, integrin alphaIIbbeta3 has been the subject of intensive investigations. Such studies have provided substantial insights into its structure-function relationships and have led to the development of anti-thrombotic drugs that target the receptor. Nevertheless, recent findings have indicated that our understanding of the structure and function of alphaIIbbeta3 remains inadequate. This article addresses two aspects of still evolving alphaIIbbeta3 function: 1) the interface between alphaIIbbeta3 and the blood coagulation system, resulting from interaction of prothrombin with the receptor; and 2) the molecular basis for recognition of the RGD and the fibrinogen gamma-chain peptide ligands by alphaIIbbeta3. As illustrated by these two examples, there is still much to be learned about alphaIIbbeta3 if we are to fully appreciate its functions and its potential as a therapeutic target.
[PUBMED: 11487023]